Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants.
Familial Mediterranean fever (FMF) is inherited autosomal recessively; however, heterozygotes may express FMF phenotype. We aimed to define the characteristics of FMF patients heterozygous for MEFV (MEditerranean FeVer) mutations in whom colchicine was stopped after a period of treatment, with close follow-up. We reviewed the charts of 182 children who were heterozygous for MEFV variants. We excluded the patients (n = 34) heterozygous for MEFV variants of unknown significance and patients with typical periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome (n = 2). All patients were followed up with their routine analysis and serum amyloid A levels every 6 months while on colchicine treatment and every 3-6 months thereafter. MEFV gene variant analysis was performed with Sanger sequencing. Twenty-two out of 146 heterozygotes initially had FMF phenotype, but colchicine was discontinued after a treatment period. The most common MEFV variant was M694V (86.3 %). The median age at diagnosis/initiation of colchicine was 76 (24-144) months. The median duration of colchicine treatment was 36 (24-110) months. The median age at colchicine cessation was 120 (55-172) months. At the time of colchicine cessation, the median attack- and inflammation-free period was 27 (24-84) months. The median follow-up after colchicine cessation was 22.5 (6-102) months. We re-started colchicine in only two patients because of recurrence of symptoms. Individuals with one mutation only can display FMF phenotype and require colchicine for the clinical and laboratory inflammation. However, in some of these patients, colchicine may be discontinued with very careful follow-up.
Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey.
Hafize Emine
HE
Sönmez
Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey.
Ezgi Deniz
ED
Batu
Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey.
Yelda
Y
Bilginer
Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, 06100, Turkey. sezaozen@hacettepe.edu.tr.
Seza
S
Özen
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003078:Colchicine / Q000009:adverse effects / Q000627:therapeutic use*; D010505:Familial Mediterranean Fever / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D014644:Genetic Variation; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007223:Infant; D007249:Inflammation; D008297:Male; D009154:Mutation; D010641:Phenotype; D012008:Recurrence; D012189:Retrospective Studies; D050257:Tubulin Modulators / Q000009:adverse effects / Q000627:therapeutic use
D050257:Tubulin Modulators; D003078:Colchicine
Colchicine; Discontinuation; Familial Mediterranean fever; Genetics; Heterozygote
Cell. 1997 Aug 22;90(4):797-807
9288758
Ann Rheum Dis. 2016 Apr;75(4):644-51
26802180
Ann Rheum Dis. 2012 Oct;71(10):1599-605
22661645
Arthritis Rheum. 2009 Jun;60(6):1851-61
19479870
Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S120-2
17067442
N Engl J Med. 1972 Dec 21;287(25):1302
4636899
Rheumatology (Oxford). 2006 Jun;45(6):746-50
16403826
Semin Arthritis Rheum. 1993 Dec;23(3):206-14
8122124
Orphanet J Rare Dis. 2014 Jan 09;9:3
24401676
Semin Immunopathol. 2015 Jul;37(4):363-9
25832989
Rheumatology (Oxford). 2009 Apr;48(4):395-8
19193696
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9982-7
16785446
Semin Arthritis Rheum. 2013 Dec;43(3):387-91
23742958
Arthritis Rheum. 2009 Jun;60(6):1862-6
19479871
Nat Genet. 1997 Sep;17 (1):25-31
9288094